The Pharma Data

JANUARY 31, 2021

Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope.

Vaccination 52

Vaccination Vaccine Trials Protein 52

Delveinsight

FEBRUARY 23, 2021

The company plans to use the capital to expand its pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag technology platform. M from BARDA for SARS-CoV-2 Antigen Test. LightDeck Diagnostics Gets USD 5.65 The approval is granted to Sanofi and Regeneron Pharmaceuticals.

In-Vitro 52

In-Vitro Vaccination Vaccine Licensing 52

The Pharma Data

MARCH 8, 2022

The development of visage SARS-CoV-2 or pansarbecovirus vaccines, as well as the development of vaccines that are suitable to evoke mucosal impunity, may be desirable options, but the timeframe for their development and product is uncertain.

Vaccination 52

Vaccination Vaccine Manufacturing Development 52

The Pharma Data

APRIL 22, 2023

Cocktail of modified antibodies provides strong effect against SARS-CoV-2 Is it possible to improve the antibodies that the body produces to fight SARS-CoV2? The researchers have access to many antibodies against SARS-CoV-2, of which eight are of the IgG3 type. The studies were carried out in human cells and with mice.

Antibody 40

Antibody Immune Response Protein Research 40

The Pharma Data

NOVEMBER 15, 2020

Peng Liang , Founder and Chief Scientific Officer of Clover and inventor of the Trimer-Tag© technology, says, “A successful vaccine that can truly modulate the course of the COVID-19 pandemic must have four essential characteristics: safety, efficacy, scalability of manufacturing, and speed.

Vaccination 52

Vaccination Vaccine Manufacturing Life Science 52

XTalks

NOVEMBER 27, 2021

The World Health Organization (WHO) has declared the new variant of SARS-CoV-2 found in South Africa, first referred to as B.1.1.529, The technical advisory group on SARS-CoV-2 virus evolution (TAG-VE) met on Friday to discuss B.1.1.529, 1.1.529, two days after it was first reported to the global health agency by South Africa.

Vaccination 97

Vaccination Vaccine Protein Scientist 97

The Pharma Data

MARCH 20, 2021

As laboratories around the world tackle the challenges of screening large numbers of samples for SARS-CoV-2, the managers of these labs have turned to the use of automation to address some key concerns. SARS-CoV-2 qPCR workflow that had been implemented over the summer at their facility. presented the. samples per day. therapeutics.

Reagent 52

Reagent RNA Bioinformatics Medicine 52

Rethinking Clinical Trials

AUGUST 4, 2022

It is a single injection of peginterferon lambda verses placebo, patients were randomized within 7 days of symptom onset and positive SARS-CoV-2 test. The arm evaluating Peginterferon Lambda is a multicenter, investigator sponsored, randomized placebo-controlled Phase 3 study in Brazil with 12 sites and Canada (5 sites).

Trials 130

Trials Vaccination Vaccine Clinical Trials 130

Delveinsight

DECEMBER 3, 2020

The FDA nods for the Elecsys Anti-SARS-CoV-2 S quantitative antibody test that runs on Roche’s cobas e analyzers, follows its September launch in Europe after receiving a CE mark. of the time and negative results 99.98% of the time, as per Roche. Merck chooses TriNKET cancer immunotherapy program.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

Drug Discovery World

NOVEMBER 13, 2023

Thereafter, the following presentations will take place: Hristo Svilenov, PhD, Associate Professor, Ghent University, on: ‘Extrinsic stabilisation of antiviral ACE2-Fc fusion proteins targeting SARS-CoV-2’. Opher Gileadi, PhD, Head, Protein Science SGC, Karolinska Institute, on: ‘Targeting every human protein: Challenges and prospects’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

Esperanza Rivera de Torre, PhD, Assistant Professor, Center for Antibody Technologies, Department of Bioengineering, Technical University of Denmark, on: ‘Venom on demand: optimising snake toxin yield, folding, and purity in E coli and P pastoris with biotinylation, solubility, and purification tags’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

MAY 4, 2021

In February 2021, Pfizer and BioNTech announced results from in vitro studies published in Nature Medicine that demonstrated that sera from individuals vaccinated with BNT162b2 neutralize SARS-CoV-2 with key mutations present in the U.K. and South African variants. The study will include participants from the Phase 1 study in the U.S.

Vaccination 40

Vaccination Vaccine Production Sales 40